AcelRx Pharmaceuticals (ACRX) : Traders are bullish on AcelRx Pharmaceuticals (ACRX) as it has outperformed the S&P 500 by a wide margin of 7.2% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.04%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 11.64% in the last 1 week, and is up 5.03% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.97% and the 50-Day Moving Average is 8.21%.The 200 Day SMA reached 2.96% AcelRx Pharmaceuticals, Inc. is up 24.13% in the last 3-month period. Year-to-Date the stock performance stands at -7.79%.
AcelRx Pharmaceuticals (ACRX) : Average target price received by AcelRx Pharmaceuticals (ACRX) is $8 with an expected standard deviation of $5.03. The most aggressive target on the stock is $15, whereas the most downbeat target is $3. 4 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. AcelRx Pharmaceuticals (NASDAQ:ACRX): stock was range-bound between the intraday low of $3.45 and the intraday high of $3.69 after having opened at $3.59 on Fridays session. The stock finally closed in the red at $3.59, a loss of -1.39%. The stock remained in the red for the whole trading day. The total traded volume was 931,080 shares. The stock failed to cross $3.69 in Fridays trading. The stocks closing price on Thursday was $3.55.
AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Companys lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.